Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Direct Mitochondrial Frataxin Delivery: CTI-1601's innovative approach directly delivers frataxin to the mitochondria, addressing the root cause of Friedreich's ataxia (FA) through a protein replacement strategy, a distinct mechanism compared to other investigational therapies.
Addressing High Unmet Medical Need: There are currently no FDA-approved disease-modifying treatments for Friedreich's ataxia, positioning CTI-1601 to potentially be the first therapy to address the underlying cause of this devastating neurodegenerative disorder.
Orphan Drug Designation Benefits: CTI-1601 has received Orphan Drug Designation (ODD) in both the US and EU for Friedreich's ataxia, providing significant regulatory and market incentives, including market exclusivity upon approval and financial benefits.
Risks
Clinical Trial Failure Risk: Clinical trials for CTI-1601 may not succeed in demonstrating efficacy or safety, leading to delays or complete failure to advance the product.
Regulatory Approval Risk: CTI-1601 may not receive the necessary regulatory approvals from health authorities such as the FDA, even if clinical trials are positive.
Funding and Dilution Risk: The company will require significant additional capital to fund its operations and development programs, which may lead to substantial dilution for current shareholders.
Today
6:01 AM
Tuesday
Jun 30, 7:06 AM
Jun 30, 5:51 AM
Monday
Jun 29, 10:24 AM
Jun 29, 6:34 AM
Over a week ago
May 27, 5:13 AM
May 18, 7:54 AM
May 15, 7:56 AM
May 14, 7:10 AM
Mar 20, 7:59 AM
Mar 19, 7:16 AM
Mar 3, 8:34 AM
Feb 25, 9:05 PM
Feb 25, 4:37 PM
Feb 25, 6:35 AM
Feb 24, 7:26 AM
Nov 5, 7:32 AM
Nov 5, 7:31 AM
Oct 2, 7:48 AM
